Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade D 10.195 -1.50% -0.16
IOVA closed up 4.12 percent on Monday, March 18, 2019, on 86 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical IOVA trend table...

Date Alert Name Type % Chg
Mar 18 Crossed Above 20 DMA Bullish -1.50%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.50%
Mar 18 Bollinger Band Squeeze Range Contraction -1.50%
Mar 18 Multiple of Ten Bullish Other -1.50%
Mar 18 Outside Day Range Expansion -1.50%
Mar 15 20 DMA Resistance Bearish 2.57%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.57%
Mar 15 Bollinger Band Squeeze Range Contraction 2.57%
Mar 15 Multiple of Ten Bearish Other 2.57%
Mar 14 Fell Below 20 DMA Bearish 1.95%

Older signals for IOVA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Oncology Cancer Treatments Cancer Immunotherapy Antineoplastic Drugs Melanoma Cell Therapy Solid Tumor Metastatic Melanoma Adoptive Cell Transfer Cancer Immunotherapy Products Head And Neck Cancers Breast And Lung Cancer National Cancer Institute Ocular Melanoma Treatment Of Metastatic Melanoma
Is IOVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 18.35
52 Week Low 7.26
Average Volume 976,552
200-Day Moving Average 11.5186
50-Day Moving Average 9.7342
20-Day Moving Average 10.3185
10-Day Moving Average 10.268
Average True Range 0.5427
ADX 16.69
+DI 21.8069
-DI 20.6144
Chandelier Exit (Long, 3 ATRs ) 9.7319
Chandelier Exit (Short, 3 ATRs ) 11.258100000000001
Upper Bollinger Band 11.0904
Lower Bollinger Band 9.5466
Percent B (%b) 0.52
BandWidth 14.961477
MACD Line 0.1284
MACD Signal Line 0.203
MACD Histogram -0.0745
Fundamentals Value
Market Cap 740.31 Million
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -4.98
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.40
Resistance 3 (R3) 11.36 10.98 11.23
Resistance 2 (R2) 10.98 10.71 11.00 11.17
Resistance 1 (R1) 10.66 10.54 10.82 10.70 11.11
Pivot Point 10.28 10.28 10.36 10.30 10.28
Support 1 (S1) 9.96 10.01 10.12 10.00 9.59
Support 2 (S2) 9.58 9.84 9.60 9.53
Support 3 (S3) 9.26 9.58 9.48
Support 4 (S4) 9.30